The Medicines for Human Use (Clinical Trials) Regulations 2004

3.  The following documents or, in each case, an explanation of why that document is not being provided—

(a)the protocol;

(b)the investigator’s brochure for the proposed trial or, where the investigational medicinal product has a marketing authorisation and the product is to be used in accordance with the terms of that authorisation, the summary of product characteristics relating to that product;

(c)any document providing evidence of any insurance to cover the liability of the sponsor and investigator;

(d)copies of the advertisement material for recruitment of research participants;

(e)in the case of advertising contained on video or audio cassettes, a copy of the script for that advertising;

(f)a copy of any letter inviting a subject to participate in the trial;

(g)a copy of any questionnaire, diary or sample card to be completed by the subject in writing;

(h)a copy of all written information to be given to a potential subject or their legal representative prior to seeking informed consent;

(i)a copy of the form to be used to record the consent of a subject or their legal representative;

(j)a copy of any letters or other written information to be sent to any person who normally provides a subject’s clinical care;

(k)a summary curriculum vitae for the chief investigator and each investigator.